Several factors influence tirzepatide's pharmacokinetics: Elimination pathway : Tirzepatide is primarily eliminated through proteolytic breakdown in the body, not through renal excretion Dose and duration of treatment : Higher doses and longer treatment periods result in greater drug accumulation Body weight : Body weight is a known covariate that can modestly affect drug exposure Steady-state concentrations : With weekly dosing, tirzepatide reaches steady-state levels after approximately 4 weeks of consistent administration According to FDA prescribing information, no dose adjustment is required for patients with renal impairment (including end-stage renal disease) or hepatic impairment, as these conditions do not significantly affect tirzepatide clearance
It doesnt have a peptide sequence because it is not a peptide-based compound, but the preservative and water meet pharmacopeial standards for sterile diluent solutions
No para consumo humano
Standard good laboratory practice (GLP) diet and fresh water were provided ad libitum
[DOI] [PMC free article] [PubMed] [Google Scholar] 83.Novak V., Milberg W., Hao Y., Munshi M., Novak P., Galica A., Manor B., Roberson P., Craft S., Abduljalil A
Login Login on Peptides Clinic